Details of the Drug

General Information of Drug (ID: DMVY6B9)

• Drug Name: PMID27109571-Compound-14
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 364.8
  Logarithm of the Partition Coefficient (xlogp); 4.5
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 5
• Chemical Identifiers:
  Formula: C19H17ClN6
  IUPAC Name: 6-chloro-N-ethyl-N-methyl-4-phenyl-3-(2H-tetrazol-5-yl)quinolin-2-amine
  Canonical SMILES: CCN(C)C1=NC2=C(C=C(C=C2)Cl)C(=C1C3=NNN=N3)C4=CC=CC=C4
  InChI: InChI=1S/C19H17ClN6/c1-3-26(2)19-17(18-22-24-25-23-18)16(12-7-5-4-6-8-12)14-11-13(20)9-10-15(14)21-19/h4-11H,3H2,1-2H3,(H,22,23,24,25)
  InChIKey: DNKGOGCNEVPJAB-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 89542132
  TTD ID: D01GOO

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fatty acid-binding protein 4 (FABP4)	TTHWMFZ	FABP4_HUMAN	Inhibitor	[1]
Fatty acid-binding protein 5 (FABP5)	TTNT2S6	FABP5_HUMAN	Inhibitor	[1]

References

• [1] Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76.